Mansoor A. Khan, PhD - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

KeywordLocation
About Search
Mansoor A. Khan, PhD


Mansoor A. Khan, PhD
Director,
FDA/CDER/DPQR

Mansoor A. Khan is the director of product quality research in the Center for Drug Evaluation and Research at the US Food and Drug Administration. Prior to joining FDA, Khan was a professor of pharmaceutics and director of graduate program in the School of Pharmacy at Texas Tech University Health Sciences Center. He is a registered pharmacist, and earned his PhD in Industrial Pharmacy from the St. John's University School of Pharmacy at New York in 1992. He has published more than 135 peer-reviewed manuscripts, four texts including Pharmaceutical and Clinical Calculations, five book chapters, and given more than 125 presentations in various meetings. Khan advised 10 PhD students in pharmaceutics.

Khan's research focus is primarily in the area of quality by design and process analytical technologies, controlled drug delivery of challenging molecules, oral delivery of macromolecules, and nanoparticles. He is the chair-elect of Pharmaceutics and Drug Delivery section of the American Association of Pharmaceutical Scientists (AAPS), and has been recognized as an AAPS fellow. He serves on the editorial board of Pharmaceutical Technology, the Journal of Clinical Research and Regulatory Affairs, and the journal Critical Reviews in Therapeutic Drug Carrier Systems.

ADVERTISEMENT

post a comment
Your email address will NOT be published.
appears with your comment
read our privacy policy
Note: does not support HTML
All comments submitted are subject to review, and may be delayed before posting. We reserve the right not to post comments.
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What factor do you think will be most significant in 2010 for determining the health of the market for contract manufacturing of active pharmaceutical ingredients?
The global economic recovery
The US economic recovery
Improved credit and financing flow to the small to emerging pharma/bio sector
Less restrictive inventory control by pharmaceutical companies
The level of competition from contract manufacturers in emerging markets
The global economic recovery
40%
The US economic recovery
14%
Improved credit and financing flow to the small to emerging pharma/bio sector
14%
Less restrictive inventory control by pharmaceutical companies
9%
The level of competition from contract manufacturers in emerging markets
24%
View Results
Eric LangerOutsourcing OutlookEric Langer A Bio View of Outsourcing
Patricia Van ArnumIngredients InsiderPatricia Van Arnum Advances in Custom Synthesis
Faiz kermaniSpotlightFaiz Kermani EU pricing dilemmas
Faiz kermaniStatistical Solutions Lynn Torbeck%RSD: Friend or Foe?
Keep an eye on that cargo
Pharma packs a punch
Another Boost for Vaccines
Rodney Dangerfield and R&D
Federal Spending Freeze Could Threaten Supply-Chain Security
FindPharma Custom Search

Click here